The FDA has approved Tecentriq® in combination with Avastin® for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
The combination resulted in durable response in many patients.
The source of fats in an individual’s diet may alter the risk of developing hepatocellular carcinoma.
For patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab is associated with longer time to deterioration of patient-reported quality of life.
Intolerance to treatment with direct acting antiviral treatment was found to be associated with older age and advanced liver disease in patients with hepatocellular carcinoma.
The median change in HCC tumor size between responders and nonresponders was statistically significant.
In this study, deterioration in specific PROs required a drop of at least 10 points from baseline.
The review authors used existing evidence to recommend a new model of palliative care integration in patients with hepatocellular carcinoma.
Researchers hypothesized that because prior studies have demonstrated that common drugs can affect the microbiome, these medications could also impact IO efficacy in HCC.
Previous genomic profiling studies have identified potentially targetable alterations in IDH1 and FGFR2 in primary tumor specimens of some patients with IHCC.
PHGDH may be a possible target for overcoming sorafenib resistance, preclinical evidence suggests.
The Food and Drug Administration (FDA) has granted Orphan Drug designation to SFA001 (SFA Therapeutics) for the treatment of hepatocellular carcinoma (HCC).
According to a recently published study, a high level of hepatitis B core-related antigen is a complementary risk factor for hepatocellular carcinoma development.
Leisure-time physical activity at recommended levels is associated with a significantly lower risk for seven cancer types.
From a nationwide Swedish registry, researchers found data that showed in patients with hepatitis B or C virus infection, the long-term hepatocellular carcinoma risk was lower in patients who were treated with lipophilic statins.
The FDA has cleared the first duodenoscope with a disposable sterile elevator piece, a first in the United States. The design will reduce the number of parts that need to be cleaned and disinfected (reprocessed) between uses.
The FDA has granted Fast Track designation to TERN-101 (Terns Pharmaceuticals) for the treatment of non-alcoholic steatohepatitis.
Study provides a portrait of wild-type AAV infection in the liver with an identification of molecular forms, viral genotypes, viral integrations, and helper virus relationship and with AAV insertions positive selected during HCC development on noncirrhotic liver, which challenges the concept of AAV as nonpathogenic.
Researchers found data that showed treatment with direct-acting antivirals in patients with hepatocellular carcinoma with advanced cirrhosis improves liver function and could be categorized as safe.
Lipophilic statins were linked to a lower risk of hepatocellular carcinoma and death in a cohort of patients with chronic hepatitis B/C.